Waystar Considers Sale Amid Software Sector Challenges
Waystar is exploring a potential sale, two years after its public listing, amid a downturn in software valuations.
Waystar, a healthcare software company known for its technology that automates administrative tasks for hospitals and doctors, is considering strategic options including a potential sale, according to sources familiar with the matter. The company, which went public two years ago, has engaged investment bank Evercore to guide the process, although discussions are still in the preliminary stages.
Headquartered in Lehi, Utah, and Louisville, Kentucky, Waystar has seen its market valuation decline to approximately $4.8 billion, following a 24% drop in its share price this year. This decline is reflective of a broader downturn in the software sector, which has experienced significant volatility as investors reassess valuations amid emerging technological advancements.
Potential Sale and Market Conditions
The potential sale of Waystar comes as the company aims to capitalize on the higher valuations typically associated with technology firms, as opposed to healthcare service providers. This strategic positioning was initially well-received by investors, propelling Waystar's shares from $20 at its initial public offering to a peak of $45 in 2025. However, recent concerns over the disruptive potential of artificial intelligence in the software industry have contributed to downward pressure on the stock.
Waystar's exploration of a sale is seen as a test of current investor appetite for software companies. The company's largest shareholders include EQT, which holds a 13% stake, the Canada Pension Plan Investment Board with 10%, and BlackRock Institutional Trust Company at 8%, according to data from LSEG.
Background and Stakeholder Responses
Formed through a merger between healthcare revenue management firms Zirmed and Navicure in 2017, Waystar has been backed by major investment entities such as EQT, Bain Capital, and the Canada Pension Plan Investment Board. These investors facilitated Waystar's transition to a publicly traded company in 2024.
While EQT and BlackRock declined to comment on the potential sale, and CPPIB did not immediately respond to inquiries, the market is closely watching to see if Waystar's auction process will attract interest from potential buyers.
As the healthcare software sector navigates a challenging economic landscape, Waystar's decision to explore a sale underscores the shifting dynamics and investor sentiment within the industry. The outcome of this process could signal broader trends for similar companies seeking to optimize their market positions amidst evolving technological and financial conditions.